𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Progression of motor and cognitive impairment in Parkinson's disease

✍ Scribed by E. Palazzini; P. Soliveri; G. Filippini; V. Fetoni; B. Zappacosta; G. Scigliano; D. Monza; T. Caraceni; F. Girotti

Publisher
Springer
Year
1995
Tongue
English
Weight
625 KB
Volume
242
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Differential progression of motor impair
Differential progression of motor impairment in levodopa-treated Parkinson's disease
✍ Christopher G. Goetz; Glenn T. Stebbins; Lucy M. Blasucci πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 2 views

OBJECTIVE: To monitor comparative progression of clinical impairment over 4 years in patients with Parkinson's disease (PD) who present on levodopa at two different levels of Hoehn and Yahr (HY) stages, II and III. BACKGROUND: The rate of clinical impairment progression in patients with PD being tr

Subtypes of mild cognitive impairment in
Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia
✍ Carmen Cristea Janvin; Jan Petter Larsen; Dag Aarsland; Kenneth Hugdahl πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Abstract The aim of this study was to establish the rate of progression from mild cognitive impairment (MCI) to dementia in patients with Parkinson's disease (PD). PD patients without dementia were recruited in 1997 from an ongoing prospective epidemiological study. The assessment included neuro

Cognitive impairment in nondemented Park
Cognitive impairment in nondemented Parkinson's disease
✍ Paolo Barone; Dag Aarsland; David Burn; Murat Emre; Jaime Kulisevsky; Daniel Wei πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 165 KB πŸ‘ 1 views

## Abstract A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools